In July 2015, Neurotherapeutics published an article about Autism spectrum disorder (ASD), presenting a modern view of the endocannabinoid (eCB) system, and alterations of its main components in human patients and animal models relevant to ASD. Our understanding of eCB signaling in autism is still in its infancy compared with other disorders of the central nervous system or of peripheral tissues, where eCB-based therapies have already reached preclinical and clinical phases. However, research in this field is rapidly evolving, and novel drugs able to hit specifically a distinct element of the eCB system are being developed at a surprising speed. (more…)
SCC, in collaboration with The Medical Cannabis Institute, launches the first online, medical cannabis curriculum that presents, in sequential order, a series of 12 courses designed to take a practicing clinician from the basics of the plant, its history and the underlying physiologic (endocannabinoid) system to the pharmacology and clinical practice of medical cannabis. Healthcare professionals can claim up to 12 CME credits (AMA PRA Category 1 Credit™), receiving a certificate of competency in clinical cannabinoid medicine upon curriculum completion. Learn More
Published in 2012, this study concluded that elevation of cannabinoid receptor activity either by pharmacological blockade of the degradation of cannabinoids or by receptor agonists could be a promising strategy for slowing down the progression of brain aging and for alleviating the symptoms of neurodegenerative disorders.